NextCure Inc (NAS:NXTC)
$ 1.385 -0.045 (-3.15%) Market Cap: 38.74 Mil Enterprise Value: -40.84 Mil PE Ratio: 0 PB Ratio: 0.45 GF Score: 39/100

NextCure Inc at JMP Securities Life Sciences Conference Transcript

May 16, 2023 / 03:30PM GMT
Release Date Price: $1.73 (+1.60%)
Unidentified Participant

All right. We'll go ahead and get started. Good morning, everyone. Welcome to the second day of The JMP Securities Life Sciences Conference. It's my pleasure to introduce NextCure.

NextCure is a biopharmaceutical company developing first-in-class immunomedicines to treat and restore the normal immune function. Here to tell us more about the company is Tim Mayer, COO.

Timothy Mayer
NextCure, Inc. - COO

Thanks, [Ren]. As Ren said, my name is Timothy Mayer, and I'm the Chief Operating Officer at NextCure. I would like to thank JMP Securities and, specifically, Ren for the invitation and the opportunity to present at today's life sciences conference. It's great to be with everyone, and I look forward to walking you through an update on NextCure and our approach to treating cancer.

So what is the NextCure opportunity? NextCure is focused on discovering and developing next-generation immunomedicines to treat cancer and other immune-mediated diseases by restoring normal immune function. We believe the NextCure opportunity is quite

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot